Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.
“Today’s authorization introduces the first treatment for COVID-19 that is in the form of a pill that is taken orally — a major step forward in the fight against this global pandemic,” said Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research. “This authorization provides a new tool to combat COVID-19 at a crucial time in the pandemic as new variants emerge and promises to make antiviral treatment more accessible to patients who are at high risk for progression to severe COVID-19.”
Paxlovid is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19. Paxlovid is not a substitute for vaccination in individuals for whom COVID-19 vaccination and a booster dose are recommended. The FDA has approved one vaccine and authorized others to prevent COVID-19 and serious clinical outcomes associated with a COVID-19 infection, including hospitalization and death. The FDA urges the public to get vaccinated and receive a booster if eligible. Learn more about FDA-approved or -authorized COVID-19 vaccines.
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations. Paxlovid is administered as three tablets (two tablets of nirmatrelvir and one tablet of ritonavir) taken together orally twice daily for five days, for a total of 30 tablets. Paxlovid is not authorized for use for longer than five consecutive days.
The issuance of an EUA is different than an FDA approval. In determining whether to issue an EUA, the FDA evaluates the totality of scientific evidence available and carefully balances any known or potential risks with any known or potential benefits of the product. Based on the FDA’s review of the totality of the scientific evidence available, the agency has determined that it is reasonable to believe that Paxlovid may be effective for the treatment of mild-to-moderate COVID-19 in authorized patients. The agency has also determined that the known and potential benefits of Paxlovid, when used consistent with the terms and conditions of the authorization, outweigh the known and potential risks of the product. There are no adequate, approved and available alternatives to Paxlovid for the treatment of COVID-19.
The primary data supporting this EUA for Paxlovid are from EPIC-HR, a randomized, double-blind, placebo-controlled clinical trial studying Paxlovid for the treatment of non-hospitalized symptomatic adults with a laboratory confirmed diagnosis of SARS-CoV-2 infection. Patients were adults 18 years of age and older with a prespecified risk factor for progression to severe disease or were 60 years and older regardless of prespecified chronic medical conditions. All patients had not received a COVID-19 vaccine and had not been previously infected with COVID-19. The main outcome measured in the trial was the proportion of people who were hospitalized due to COVID-19 or died due to any cause during 28 days of follow-up. Paxlovid significantly reduced the proportion of people with COVID-19 related hospitalization or death from any cause by 88% compared to placebo among patients treated within five days of symptom onset and who did not receive COVID-19 therapeutic monoclonal antibody treatment. In this analysis, 1,039 patients had received Paxlovid, and 1,046 patients had received placebo and among these patients, 0.8% who received Paxlovid were hospitalized or died during 28 days of follow-up compared to 6% of the patients who received placebo. The safety and effectiveness of Paxlovid for the treatment of COVID-19 continue to be evaluated.
Possible side effects of Paxlovid include impaired sense of taste, diarrhea, high blood pressure and muscle aches. Using Paxlovid at the same time as certain other drugs may result in potentially significant drug interactions. Using Paxlovid in people with uncontrolled or undiagnosed HIV-1 infection may lead to HIV-1 drug resistance. Ritonavir may cause liver damage, so caution should be exercised when giving Paxlovid to patients with preexisting liver diseases, liver enzyme abnormalities or liver inflammation.
Because Paxlovid works, in part, by inhibiting a group of enzymes that break down certain drugs, Paxlovid is contraindicated with certain drugs that are highly dependent on those enzymes for metabolism and for which elevated concentrations of certain drugs are associated with serious and/or life-threatening reactions. Paxlovid is also contraindicated with drugs that, conversely, strongly induce those same enzymes, leading to the faster breakdown of nirmatrelvir or ritonavir, as reduced concentrations of nirmatrelvir or ritonavir may be associated with potentially losing virologic response and developing viral resistance. Paxlovid cannot be started immediately after discontinuing such medications because the effects of those medications remain after discontinuation. For a complete list of drugs that should not be taken in combination with Paxlovid, see the fact sheet for healthcare providers.
Paxlovid is not recommended in patients with severe kidney or severe liver impairment. In patients with moderate renal impairment, a reduced Paxlovid dose is needed. Patients with kidney or liver problems should discuss with their healthcare provider whether Paxlovid is right for them.
Under the EUA, fact sheets that provide important information about using Paxlovid in the treatment of COVID-19 as authorized must be made available to healthcare providers and to patients and caregivers. These fact sheets include dosing instructions, potential side effects, drug interactions and information about who is able to prescribe Paxlovid.
News
In a first for China, Neuracle’s implantable brain-computer interface wins approval
In a landmark development, Neuracle Medical Technology has secured the country’s first-ever approval for an implantable brain-computer interface (BCI) system designed to restore hand motor function in patients with spinal cord injuries, in a [...]
A Cambridge Lab Mistake Reveals a Powerful New Way to Modify Drug Molecules
A surprising lab discovery reveals a light-powered way to tweak complex drugs faster, cleaner, and later in development. Researchers at the University of Cambridge have created a new technique for altering complex drug molecules [...]
New book from NanoappsMedical Inc – Molecular Manufacturing: The Future of Nanomedicine
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
Scientists Discover Simple Saliva Test That Reveals Hidden Diabetes Risk
Researchers have identified a potential new way to assess metabolic health using saliva instead of blood. High insulin levels in the blood, known as hyperinsulinemia, can reveal metabolic problems long before obvious symptoms appear. It is [...]
One Nasal Spray Could Protect Against COVID, Flu, Pneumonia, and More
A single nasal spray vaccine may one day protect against viruses, pneumonia, and even allergies. For decades, scientists have dreamed of creating a universal vaccine capable of protecting against many different pathogens. The idea [...]
New AI Model Predicts Cancer Spread With Incredible Accuracy
Scientists have developed an AI system that analyzes complex gene-expression signatures to estimate the likelihood that a tumor will spread. Why do some tumors spread throughout the body while others remain confined to their [...]
Scientists Discover DNA “Flips” That Supercharge Evolution
In Lake Malawi, hundreds of species of cichlid fish have evolved with astonishing speed, offering scientists a rare opportunity to study how biodiversity arises. Researchers have identified segments of “flipped” DNA that may allow fish to adapt rapidly [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Scientists Discover Why Some COVID Survivors Still Can’t Taste Food Years Later
A new study provides the first direct biological evidence explaining why some people continue to experience taste loss long after recovering from COVID-19. Researchers have uncovered specific biological changes in taste buds that could help [...]
Catching COVID significantly raises the risk of developing kidney disease, researchers find
Catching Covid significantly raises the risk of developing deadly kidney disease, research has shown. The virus was found to increase the chances that patients will develop the incurable condition by around 50 per cent. [...]
New Toothpaste Stops Gum Disease Without Harming Healthy Bacteria
Researchers have developed a targeted approach to combat periodontitis without disrupting the natural balance of the oral microbiome. The innovation could reshape how gum disease is treated while preserving beneficial bacteria. The human mouth [...]
Plastic Without End: Are We Polluting the Planet for Eternity?
The Kunming Montreal Global Biodiversity Framework calls for the elimination of plastic pollution by 2030. If that goal has been clearly set, why have meaningful measures that create real change still not been implemented? [...]
Scientists Rewire Natural Killer Cells To Attack Cancer Faster and Harder
Researchers tested new CAR designs in NK-92 cells and found the modified cells killed tumor cells more effectively, showing stronger anti-cancer activity. Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based [...]
New “Cellular” Target Could Transform How We Treat Alzheimer’s Disease
A new study from researchers highlights an unexpected player in Alzheimer’s disease: aging astrocytes. Senescent astrocytes have been identified as a major contributor to Alzheimer’s progression. The cells lose protective functions and fuel inflammation, particularly in [...]
Treating a Common Dental Infection… Effects That Extend Far Beyond the Mouth
Successful root canal treatment may help lower inflammation associated with heart disease and improve blood sugar and cholesterol levels. Treating an infected tooth with a successful root canal procedure may do more than relieve [...]
Microplastics found in prostate tumors in small study
In a new study, researchers found microplastics deep inside prostate cancer tumors, raising more questions about the role the ubiquitous pollutants play in public health. The findings — which come from a small study of 10 [...]
